Complications of Peripherally Inserted Central Venous Catheters: A Retrospective Cohort Study by Paz Zulueta, María et al.
RESEARCH ARTICLE
Complications of Peripherally Inserted
Central Venous Catheters: A Retrospective
Cohort Study
Paula Parás-Bravo1☯*, María Paz-Zulueta1☯, Raquel Sarabia-Lavin1☯, Francisco Jose
Amo-Setién1, Manuel Herrero-Montes2, Encarnación Olavarría-Beivíde2,
Mercedes Rodríguez-Rodríguez2, Blanca Torres-Manrique2, Carlos Rodríguez-de la
Vega2, Vanesa Caso-Álvarez2, Laura González-Parralo2, Francisco Manuel Antolín-
Juárez2☯
1 Departamento de Enfermería, Universidad de Cantabria, Santander, Cantabria, España, 2 Servicio
Cántabro de Salud, Santander, Cantabria, España




The use of venous catheters is a widespread practice, especially in oncological and onco-
hematological units. The objective of this study was to evaluate the complications associ-
ated with peripherally inserted central catheters (PICCs) in a cohort of patients.
Materials and Methods
In this retrospective cohort study, we included all patient carrying PICCs (n = 603) inserted
at our institute between October 2010 and December 2013. The main variables collected
were medical diagnosis, catheter care, location, duration of catheterization, reasons for
catheter removal, complications, and nursing care. Complications were classified as infec-
tion, thrombosis, phlebitis, migration, edema, and/or ecchymosis.
Results
All patients were treated according to the same “nursing care” protocol. The incidence rate
of complications was two cases per 1000 days of catheter duration. The most relevant com-
plications were infection and thrombosis, both with an incidence of 0.17 cases per 1000
days of the total catheterization period. The total average duration of catheterization was
170 days [SD 6.06]. Additionally to “end of treatment” (48.42%) and “exitus”, (22.53%) the
most frequent cause of removal was migration (displacement towards the exterior) of the
catheter (5.80%).
Conclusions
PICCs are safe devices that allow the administration of long-term treatment and preserve
the integrity of the venous system of the patient. Proper care of the catheter is very
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important to improve the quality life of patients with oncologic and hematologic conditions.
Therefore, correct training of professionals and patients as well as following the latest scien-
tific recommendations are particularly relevant.
Introduction
The use of central venous lines is justified by the need to instill certain treatments in a continu-
ous manner and in large doses. These catheters are essential to modern medical practice, and
they are especially necessary when the treatments are vesicants or irritating, such as chemo-
therapy and some antibiotics. Central venous catheters are even indicated in the absence of
peripheral venous access or when this is very damaged [1].
At present, central venous catheter use has become widespread in medical specialties includ-
ing critical care, dialysis, nutritional support, and oncology. The most frequent indications for
their use are the administration of chemotherapy, parenteral nutrition, and treatments consid-
ered vesicants or irritating [2, 3]. Typically, these devices are used for patients with complicated
venous access, impairment of the lymphatic system, pain during infusion, and fear of veni-
puncture. Additionally, the placement of a central venous catheter for outpatient administra-
tion of drugs is necessary in patients with continuous perfusion of chemotherapy. Otherwise,
the patient would require hospital admission for administration through the peripheral venous
line. Thanks to the placement of a central venous catheters in such cases, the latter circum-
stance has been practically eliminated at our hospital.
For the administration of large volumes of chemotherapy drugs, oncohematological patients
need catheters that flow into a vein with sufficient flow and caliber. Long-term peripherally
inserted central catheters (PICCs) (Fig 1) that flow into the lower third of the vena cava meet
these criteria and reduce damage of the peripheral vascular system, which favors the mainte-
nance of their integrity [4].
Using a PICC, the risk of extravasation is markedly reduced, which is particularly relevant
for the administration of drugs of a vesicant or irritating nature such as some cytostatics.
Although this type of venous port represents a safe method of permanent access with a low rate
of complications [5], some complications may still occur. Of all complications, infection and
thrombosis are the most important owing to their relevance and clinical consequences for
oncohematological patients. Such complications may be associated with increased morbidity
and depending on the baseline situation of the patient, may even increase mortality. Deep vein
thrombosis is the most common complication in patients receiving chemotherapy, and the risk
is increased in patients with diabetes, chronic obstructive pulmonary disease, or presence of
metastases [6]. The risk of infection is greater for oncohematological patients because the treat-
ment and the pathology itself are associated with periods of immunosuppression [7].
The general objective of this study was to evaluate the incidence rate of complications associated
with PICCs in a hospital in northern Spain with a cohort of mostly oncohematological patients.
Materials and Methods
Study design
This was a retrospective longitudinal cohort study.
Setting
This study was conducted in the Day Hospital, Marqués de Valdecilla University Hospital, in
Cantabria, a region in northern Spain, between October 2010 and December 2013.
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Participants
The inclusion criteria were as follows: male or female patients,18 years of age and carriers of
PICCs during the study period. Data collection was retrospective.
The study population included all the patients’ carriers of PICCs during the study period,
who were treated at our institution. The final study population was 603 patients.
Variables and Measures
The following baseline data were obtained for each patient: date of birth, sex, medical diagno-
sis, nursing care of the catheter, the location of the catheter, duration of catheterization (days),
reasons for catheter removal, and complications.
Catheters were inserted by trained nursing staff, by sterile and ultrasound-guided technique
(two-dimensional ultrasound imaging). The PICCs were placed in the middle third of the
upper arm, above the antecubital fossa, in either the cephalic or basilic vein. We chose a vein of
a caliber proportional to the caliber of the catheter. The distal tip of the catheter was placed in
the lower third of the superior vena cava, which was later confirmed by chest radiograph [8].
We used PowerPicc1, a polyurethane, 5-Fr diameter, single-lumen catheter. Fixation and sta-
bilization was achieved with a sterile latex-free device designed for this purpose (StatLock
PICC Plus Stabilization Device1).
The “Nursing protocol” was applied to all patient carriers of PICCs and consisted of weekly
sterile dressing with transparent bandages and cleaning with chlorhexidine solution according
to the recommendations of the United States Centers for Disease Control and Prevention
(CDC) [9]. When the fixing device was deteriorated, it was replaced with a new one. The cathe-
ters were sealed with heparin after use [10, 11].
Fig 1. Long-term peripherally inserted central catheters (PICCs).
doi:10.1371/journal.pone.0162479.g001
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The duration of catheterization was calculated as the difference between the date of inser-
tion and the date of removal. This date was handled in the analyses like a continuous quantita-
tive variable.
Complications were categorized as infection, thrombosis, phlebitis, migration, edema, and/
or ecchymosis. The criteria for defining the occurrence of “infection” were the Central Line
Associated Blood Stream Infection (CLABSI) [9].
Symptoms of thrombosis were pain, swelling, erythema and vein blockage by a blood clot
(thrombus) with subsequent lack of permeability [12]. The criteria for the diagnosis of “throm-
bosis” were the presence of symptoms and final confirmation by ultrasound.
Phlebitis was defined as irritation of the venous endothelium by the catheter. Its symptoms
were similar to those of thrombosis, but the catheter remained permeable because there was no
venous blockage: pain, tenderness, swelling, erythema, palpable venous cord, purulent dis-
charge, and warmth of the area [13]. The criteria for a diagnosis of “phlebitis” were the pres-
ence of symptoms and final confirmation by ultrasound.
The criterion for catheter migration was outward displacement of the catheter by more than 2
cm (displacement towards the exterior). The diagnostic criterion for edema was swelling caused
by fluid accumulation in the arm near the catheter insertion point. The criterion for the diagnosis
of ecchymosis was the presence of a bruise near the catheter insertion point. The catheter was
considered to have a “lumen occlusion” if there was total occlusion, occlusion to flush only,
occlusion for aspiration only, or subjective difficulty with flushing or aspiration only, if the vein
was not damaged, inflamed or obstructed and fibrinolytic treatment was required [8, 10].
Study limitations
In retrospective studies based on secondary information (medical records), one of the main
limitations is that the data obtained from computer records may be subject to bias by the
researcher who collected the information. In this study, the personnel of the unit responsible
for the care of the PICCs was trained for data collection by standardized training sessions with
the objective of reducing the interobserver differences as much as possible.
Additionally, another study limitation is that the nursing protocol has been currently
updated. At the present time, it is recommended to clean the catheter with saline [8]. However,
this study was conducted between October 2010 and December 2013, and our protocol at that
time consisted of the prophylactic use of heparin [11, 14].
Statistical analyses
For the descriptions of the variables, frequency distributions, averages with 95% confidence intervals
(95% CI), standard deviations, and ranges were calculated. The normal distribution of data was
assessed using the Kolmogorov-Smirnov test. The cumulative incidence and the incidence density
rates per 1000 days of catheter use of the various complications were calculated. For comparison of
proportions, a chi-square test was performed, using Fisher’s exact test when necessary. Nonparamet-
ric tests were used, such as theMann-Whitney U-test, for the comparison of averages, and the Ken-
dall test was used in the correlation studies when the variables did not have a normal distribution.
For the study of associated independent factors, an automated stepwise forward multiple logistic
regression model was used. The alpha error was set at 0.05, and all p-values were bilateral. All statis-
tical analyses were conducted using IBM SPSS Statistics version 22.0 (IBMCorp., Armonk, NY).
Ethics Statement
Approval of the research protocol was obtained on February 25, 2014 from the Clinical
Research Ethics Committee of Cantabria before the acquisition of data. Patient records/date
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were anonymized and de-identified prior to analysis. Because the data were analyzed anony-
mously, patient consent was not necessary. We obtained the consent of the Ethics Committee
and authorization from the hospital to perform this study.
Results
A total of 603 patient carriers of PICCs aged between 18 and 95 years (Table 1) were analyzed.
Regarding sex, 54.73% were female, and 45.27% were male.
With regard to diagnosis, 93.86% (n = 566) of the patients had been diagnosed with an
oncologic or oncohematologic disease, while the remaining patients presented with diseases of
other etiologies (Table 2). The proportion of oncological diseases was higher than that of onco-
hematological diseases; the former constituted nearly 74% of the patients (n = 466).
The average duration of catheterization was 171.20 days [SD 6.06] with a minimum of 2
days and a maximum of 882 days. All the catheters were located in the middle third of the
upper arm, above the antecubital fossa: 34.99% (n = 211) were placed in the right basilic vein,
56.05% (n = 338) were placed in the left basilic vein, 2.98% (n = 18) were placed in the right
cephalic vein, and 5.97% (n = 36) were placed in the left cephalic vein.
At least one complication occurred in 38.14% of the patients (n = 230), whereby the inci-
dence of complications was two complications per 1000 days of the total duration of catheteri-
zation. The individual analysis of complications is presented in Table 3.
Additionally, 3.15% (95% CI 1.67–4.63%) (n = 19) of patients presented an infection profile.
Complication onset after catheterization occurred at an average of 114.26 [SD 22.21] days. The
incidence rate of complications was 0.17 cases per 1000 days for the total duration of
catheterization.
Thrombosis occurred in 3.32% (95% CI 1.81–4.83%) (n = 20) of the patients, at an average
onset of 28.90 [SD 9.12] days of the total duration of catheterization. The incidence rate of
thrombosis was 0.17 cases per 1000 days of the total duration of catheterization. In 13 of the
patients, a fibrinolytic agent was used at least once. In all cases, the thrombosis event was local.
In 7.13% (95% CI 4.99–9.27%) (n = 43) of patients, phlebitis was registered at an average
onset of 2.23 [SD 0.21] days after catheter insertion. The incidence rate was 0.38 cases per 1000
days of the total catheter days.
In 13.10% (95% CI 10.32–15.88%) (n = 79) of the catheters, at least one episode of migration
was registered at an average onset of 163.75 [SD 14.15] days after insertion. The latest case
occurred on day 605. The incidence rate was 0.69 cases per 1000 days of the total duration of
catheterization.
Table 1. Age distribution of patients with peripherally inserted central catheters. Cantabria (Spain):
patient carriers of peripherally inserted central catheters, 2010–2013.
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In 9.12% (n = 55) (95% CI 10.32–15.88%) of patients, edema onset occurred at an average
onset of 28.16 [SD 9.36] days of the total duration of catheterization. In 20 patients, this com-
plication occurred on the day following catheter insertion. In contrast, four cases were regis-
tered between days 237 and 282 of catheterization. The incidence rate was 0.50 cases per 1000
days of the total duration of catheterization.
In 18.40% (n = 111) (95% CI 15.23–21.58%) of patients, an ecchymosis was produced at an
average onset of 3.96 [SD 0.42] days of the total duration of catheterization, although a high
frequency of cases (n = 47) was noted on the day following catheter insertion. This complica-
tion showed the highest incidence rate, with 1.93 cases per 1000 days of the total duration of
catheterization.
In 44.27% (95% CI 40.23–48.32) (n = 267) of the patients, a fibrinolytic therapy was used at
least once because of catheter lumen occlusion. The incidence rate was 2.32 cases per 1000 days of
the total duration of catheterization. The average onset was at 76.48 [SD 73.66] days after insertion.
Table 2. Distribution diagnosis of patients with peripherally inserted central catheters. Cantabria
(Spain): patient carriers of peripherally inserted central catheters, 2010–2013.
MEDICAL DIAGNOSIS n = 603 (%)
Colorectal cancer 149 24.70
Breast cancer 106 17.58
Non Hodgkin lymphoma 49 8.13
Pancreas cancer 44 7.30
Sarcoma 33 5.47
Leukemia 31 5.14
Hodgkin lymphoma 25 4.15
Ovarian cancer 23 3.81
Lung cancer 22 3.65
Bladder cancer 15 2.49
Gastric cancer 15 2.49
Infection 13 2.16
Ischemia chronicle 12 2.00
Head neck cancer 9 1.49
Not collected 8 1.33
Malabsorption syndrome 7 1.16
Anal cancer 5 0.83
Multiple myeloma 5 0.83
Testicles cancer 4 0.66
Esophagus cancer 4 0.66
Anemia 4 0.66
Cervix cancer 4 0.66
Prostate cancer 2 0.33
Melanoma 2 0.33
Prostate cancer 2 0.33
Kidney cancer 2 0.33
Myelodysplastic syndrome 2 0.33
Biliary cancer 1 0.16
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No significant differences were identified regarding sex, age, medical diagnosis, and location
of the catheter with respect to infection, thrombosis, phlebitis, migration, edema, ecchymosis,
and/or lumen occlusion. No variable remained significant in the multivariable model (Table 4).
No correlation was found (correlation coefficient 0.0023; p = 0.379) between age and dura-
tion, location, and migration (displacement towards the exterior) of the catheter. However, the
Table 3. Analysis of complications of peripherally inserted central catheters. Cantabria (Spain): patient carriers of peripherally inserted central cathe-
ters, 2010–2013.
COMPLICATION n (%) 95%IC Incidence ratea Day of onsetb
Infection 19 3.15 1.67–4.63 0.17 114.26 [22.21]
Thrombosis 20 3.32 1.81–4.83 0.17 28.90 [9.12]
Phlebitis 43 7.13 4.99–9.27 0.38 2.23 [0.21]
Migration 79 13.10 10.32–15.88 0.69 163.75 [14.15]
Edema 5 9.12 10.32–15.88 0.50 28.16 [9.36]
Ecchymosis 111 18.40 15.23–21.58 1.93 3.96 [0.42]
Lumen occlusion 267 44.27 40.23–48.32 2.32 76.48 [73.66]
a Per 1.000 days of use.
b Mean [SD]. Abbreviations: IC, confidence interval; SD, standar deviation.
doi:10.1371/journal.pone.0162479.t003
Table 4. Presence of complications regarding sex, age, diagnosis, and localization of the peripherally inserted central catheters. Cantabria




Men 273 99 16.41
Women 330 131 21.72
p 0.0388b
AGE
>65 years 180 65 10.78
<65 years 423 165 27.36
p 0.503b
MEDICAL DIAGNOSIS
Oncohematologic 114 36 5.97
Oncologic 445 179 29.68
Other / not collected 44 15 2.49
p 0.238b
LOCATION
Basilic right 211 72 11.94
Basilic left 338 134 22.22
Cephalic right 18 6 0.99
Cephalic left 36 18 2.98
p 0.252b
DURATION
>150 days 298 130 21.56
<150 days 305 100 16.58
p 0.006b
aPresence of at least one of the following complications: Infection, thrombosis, phlebitis, migration, edema, ecchymosis and/or lumen occlusion.
bPearson's chi-squared test.
doi:10.1371/journal.pone.0162479.t004
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complication rate was significantly higher when the total duration of catheterization was or
exceeded 150 days (p = 0.006), appearing in 43.62% (n = 130) of cases compared with 32.78%
(n = 100).
Regarding the reason for removal of the catheter, in 48.42% (n = 292) of patients, the reason
was “end of treatment”; other reasons included “exitus” in 22.55% (n = 136), “migration” in
5.80% (n = 35), “infection” in 4.14% (n = 25), “lumen occlusion” in 4.14% (n = 25), “replace-
ment” in 1.99% (n = 12), and “thrombosis/thrombophlebitis/phlebitis” in 1.82% (n = 11) of
patients. In 11.11% (n = 67) of the patients, the reason was not recorded or the cause was
unknown (Table 5).
Discussion
The care of PICCs is a common practice for nursing professionals [15]; however, on some
occasions, our actions are not supported by evidence-based practice [16–19]. Some studies
agree that the difference in the rate of complications is directly related to the knowledge of
nursing personnel regarding catheter placement and care. The rate of complications is signifi-
cantly lower when training is adequate [4, 20, 21]. In fact, the CDC states in its guide for the
care of central venous catheters that training of personnel is a fundamental aspect of preventing
infections with a level of evidence of 1A [9]. Therefore, insertion and care of these catheters
constitutes a priority area for research in nursing, not only to reduce the adverse effects but
also to improve the patient experience [17].
Compared with other published studies, our rates of infection and thrombosis were lower
(0.17 cases per 1000 days of the total catheter days) and showed cumulative incidences of
3.15% and 3.32%, respectively.
With regard to infection, in 2013, the National Healthcare Safety Network reported the inci-
dence rate of infection of laboratory-confirmed temporary catheter use in oncohematological
patients, which increased to 0.25 per 1000 days of total PICC duration [22]. Chopra et al. [23]
examined this matter in a systematic review with meta-analysis. After reviewing 57,250 patients
from 23 studies, they concluded that the incidence rate of bacteremia (collected in 13 of the
studies) in PICC patients was 0.91% (95% CI 0.46–1.79) cases per 1000 days of total PICC
duration. Another study conducted in a French university hospital with 222 patients reported
an overall infection rate of 2.35 per 1000 days of catheter use with an incidence of 0.86 cases
per 1000 days of total PICC duration [20]. Baxi et al. [24] found 57 cases of bacteremia when
studying 609 patients with an incidence rate of 2.69/1000 PICCs/day. However, none of these
studies exclusively included oncohematological patients. The study by Mollee et al. [25] was
the most similar to our own. In their study, they retrospectively evaluated 727 oncohematologi-
cal patients and found an incidence rate of infection of 2.5 per 1000 days of catheter use.
Table 5. Reasons for catheter removal of peripherally inserted central catheters. Cantabria (Spain):
patient carriers of peripherally inserted central catheters, 2010–2013. Abbreviations: IC, confidence interval.
CAUSE OFWITHDRAWAL n = 603 (%) 95%IC
End of treatment 292 48.42 44.35–52.50
Exitus 136 22.53 19.13–25.97
Migration 35 5.80 3.85–7.75
Infection 25 4.14 2.47–5.82
Lumen Occlusion 25 4.14 2.47–5.82
Replacement 12 1.99 0.79–3.18
Phlebitis or thrombosis 11 1.82 0.67–2.97
Not collected 67 11.11 8.52–13.70
doi:10.1371/journal.pone.0162479.t005
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Additionally, Aw et al. [6] studied cancer patients with a cumulative infection incidence rate of
5.6% compared with our rate of 3.15%.
With respect to thrombosis, our results yielded an incidence rate lower than expected
with 0.17 cases per every 1000 days of PICC use and a cumulative incidence of 3.32%. Baxi
et al. [24] also assessed this variable and obtained an incidence rate of 1.23/1000 PICC days.
The cumulative incidence was approximately 8.4% in a study conducted in neurological
patients in intensive care, in which 431 patients with PICCs [26] were studied. However, Aw
et al. [6] studied a population of only 340 cancer patients of which 19 presented infection,
comprising 5.6% (95% CI (3.06–8.06) of the patient total. Their patients resembled our
patient sample in terms of characteristics; nonetheless, the complication rate in our study
was lower.
Malpositioning of the catheter tip can cause difficulties with blood withdrawal and contrib-
ute to catheter occlusion. Therefore, it is very important to check its position radiologically to
reduce this complication [8]. It is necessary to avoid occlusions because these are also associ-
ated with infection and thrombosis [10]. Further, placement of catheters above the antecubital
fossa diminishes the likelihood of thrombophlebitis [8].
It is worth mentioning that the duration of catheterization in our study was much longer
than those in the previously mentioned studies [20, 22, 23]. This was even true in some cases
of catheterization longer than 2 years, with an average of 6 months. This may be attributable
to the low rate of complications, which thereby contributed to maintaining the catheter for a
longer period of time. This is especially relevant for oncohematological patients because
they can conclude their treatment without changing devices. However, it must also be noted
that the rate of complications in our study began to increase after 150 days of catheteriza-
tion, increasing to a rate of 43.62% (n = 13). We could not compare these data because we
were unable to find a similar study that achieved a duration of catheterization similar to
ours.
The heterogeneity between the study results is justified by the differences between patients
and the care applied to the catheters. There is significant variability in the recommendations
for their care [27, 28]. In our case, following the latest recommendations at the time of the
study [9], the insertion was performed in an echo-guided manner, which reduces complica-
tions [29]. Additionally, patient handling was performed in a sterile and systematic manner
almost exclusively by the same functional unit with personnel trained for this purpose.
With respect to the “nursing protocol” that was applied to all patients by professionals
trained in PICC care in a systematic manner, we consider that this aspect is partly responsible
for the low rate of complications. However, currently, washing the catheter with saline is rec-
ommended, and therefore, our “nursing protocol” needs to be updated [8]. Perhaps with these
new recommendations, we can decrease the incidence rate of lumen occlusion.
Finally, we consider that the catheter material also influenced our incidence of complica-
tions. In our case, the material used was polyurethane, and this is relevant because polyure-
thane PICC lines have been associated with lower rates of infection, dislodgment, thrombus,
and rupture complications [30].
One of the main limitations of retrospective studies based on secondary information (medi-
cal records), could be the low quality of the information, owing either to incomplete records or
a lack of agreement among the different records. In our study, information about the main var-
iables was collected in more than 90% of patients. We were only unable to find the catheter
removal cause in 67 cases. Another aspect to consider is the lack of availability of other poten-
tial confounders (e.g., presence of metastases), which are unavailable from the secondary regis-
ters used in our study.
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Conclusions
In conclusion, the complication incidence rate was very low, considering that complications
included ecchymosis, edema, and lumen occlusion. The latter were transient and not serious
complications that did not require removal of the catheter. We will continue our line of
research and study of the relationship between our nursing care and the appearance of
complications.
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